New York Health Care Inc. (BBAL/BBAL.PK) Wrap Up:

New York Health Care, Inc., a development stage biopharmaceutical company, engages in the identification, licensing, and development of treatments for gastrointestinal disorders. Its lead product, PROBACTRIX, is a proprietary strain of E.coli M-17 bacteria, which is under clinical studies as a prescription drug treatment for pouchitis, irritable bowel syndrome, ulcerative colitis, crohn?s disease, celiac disease, IBD, and C. difficile infections, as well as for diarrhea caused by antibiotics, chemotherapy, and travel. The company also conducts clinical studies in farm animals to support the use of PROBACTRIX as a veterinary feed additive to replace antibiotics and/or animal growth hormones, as well as holds rights to a combination of Bacillus strains for treating gastrointestinal disorders. In addition, it provides home health and personal care support services, including assistance with personal hygiene, dressing and feeding, meal preparation, light housekeeping and shopping, and physical therapy, as well as nursing services, such as changing of dressings, injections, and administration of medications. New York Health Care offers home healthcare services pursuant to contracts with healthcare institutions and governmental agencies in the United States. The company was founded in 1983 and is headquartered in Brooklyn, New York.